來了!我國首個mRNA新冠疫苗生產車間在玉溪交付
近日,我國第一個mRNA新冠疫苗生產車間在玉溪高新區疫苗產業園建成並交付使用。

mRNA新冠疫苗由軍事科學院軍事醫學研究院、蘇州艾博生物科技有限公司與雲南沃森生物技術股份有限公司共同研製,玉溪沃森生物技術有限公司負責基地建設,這個基地總投資5.2億元,預計每年可生產2億劑疫苗,是我國第一個mRNA新冠疫苗產業化基地。
mRNA是一種天然分子,爲人體細胞提供指令,激發人體免疫製造抗原,對抗相應的病體。將編碼S蛋白的mRNA基因直接注入人體,利用人體細胞在人體內合成S蛋白,刺激人體產生抗體。通俗的說,相當於把一份記錄詳細的病毒檔案交給人體的免疫系統。mRNA疫苗是目前全球公佈的三期臨牀試驗結果保護率最高(95%)的疫苗。同時,其研發技術門檻高,目前僅有美國和德國研發的少數幾個mRNA疫苗品種進入臨牀研究階段 。相比國外研發的mRNA疫苗,國產mRNA疫苗具備着三大優勢。
其一,疫苗安全性更高。我國採用的疫苗抗原靶標選擇更爲精確,誘導產生的中和抗體特異性高。
其二,國產化水平高。中國mRNA疫苗核心原料和設備已經全部實現了國產化,意味着一旦獲得生產批準,那麼產能將可以實現快速放大,滿足供給。
其三,儲存成本更低。我國採用了單人份預充針劑型,可在室溫保存一週或在4℃長期保存,冷鏈成本低,容易實現人羣大規模接種。
當下,除了mRNA疫苗研發進度順利,中國基於傳統技術的重組疫苗已經走在了國際前列。據統計,截至目前,我國已有5款疫苗項目進入三期臨牀試驗,並已在十餘個國家啓動接種,且無嚴重不良反應報告。
來源|雲視新聞七彩雲
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.